Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - omeprazole magnesium - tablets gastro-resistant - 20 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - omeprazole magnesium - tablets gastro-resistant - 40 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - omeprazole magnesium - tablets gastro-resistant - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

stasisport pharma n.v. - ibuprofen - film coated tablet - 200 milligram - propionic acid derivatives - anti-inflammatory and antirheumatic products, nonsteroids; propionic acid derivatives. - for short-term symptomatic treatment of: - pain of mild to moderate intensity. - dysmenorrhoea with no organic cause. - fever in adults and adolescents.

Ireland - English - HPRA (Health Products Regulatory Authority)

stasisport pharma n.v. - ibuprofen - film coated tablet - 400 milligram - propionic acid derivatives - anti-inflammatory and antirheumatic products, nonsteroids; propionic acid derivatives. - for short term symptomatic treatment of: pain of mild to moderate intensity. fever in adults and adolescents. dysmenorrhoea with no organic cause. for symptomatic treatment of rheumatoid arthritis, arthrosis

Ireland - English - HPRA (Health Products Regulatory Authority)

stasisport pharma n.v. - ibuprofen - film coated tablet - 600 milligram - propionic acid derivatives - anti-inflammatory and antirheumatic products, non-steroids, propionic acid derivative - rheumatoid arthritis, arthrosis.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules in the treatment of adhd was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met dsm-iv® criteria for adhd [see clinical studies (14)]. a diagnosis of adhd (dsm-iv®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accou

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

laboratories torrent (malaysia) sdn. bhd. - pramipexole dihydrochloride monohydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

laboratories torrent (malaysia) sdn. bhd. - pramipexole dihydrochloride monohydrate -